A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients

Exclusion Criteria

• •1. Diagnosed as other active depigmentation disease.
• •2. At screening or baseline visits, subject exhibits active inflammatory dermatologic disease or symptoms that in the opinion of investigators would interfere of vitiligo evaluation or response to treatment.
• •3. Uncontrolled thyroid function at screening as determined by the investigator.
• •4. Use of permanent depigmentation treatment or skin grafts.
• •5. Use of phototherapy, topical or systemic treatments within certain time frame prior to Day1.
• •6. Have active bacterial/virus/other pathogens infection or infestation that require medical intervention.
• •7. Have progressive or uncontrolled systemic disease, or other concomitant chronic disease that the investigators believe unsuitable to participate the study.
• •8. History of alcohol and drug abuse within one year prior to screening; History of neurological or mental disorders with diagnosis records, such as severe depression, suicidal tendencies, epilepsy, dementia, etc.